Land: Ástralía
Tungumál: enska
Heimild: Department of Health (Therapeutic Goods Administration)
carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg); levodopa, Quantity: 100 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: quinoline yellow aluminium lake; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; crospovidone
Oral
100 tablets
(S4) Prescription Only Medicine
LEVODOPA/CARBIDOPA GenPar is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GenPar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.
Visual Identification: Round, light yellow uncoated tablets with 'C' on one side and '19' on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2018-01-11